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Quinoline derivativesAbstract In an attempt to ﬁnd new pharmacologically active molecules, we report here the
synthesis and in vitro antimicrobial activity of various 2-(2-chloro-6-methyl(3-quinolyl))-
3-[2-(4-chlorophenyl)-4-oxo(3-hydroquinazolin-3-yl)]-5-[(aryl)methylene]-1,3-thiazolidin-4-ones. In
vitro antimicrobial activity of the title compounds are screened against two Gram positive bacteria
(Staphylococcus aureus, Streptococcus pyogenes), two Gram negative bacteria ( Escherichia coli,
Pseudomonas aeruginosa) and three strains of fungi (Candida albicans, Aspergillus niger, Aspergillus
clavatus) using broth micro dilution method. Some derivatives bearing chloro or hydroxy group
exhibited very good antimicrobial activity.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Quinazoline derivatives represent one of the most active classes
of compounds possessing a wide spectrum of biological
activity (Apfel et al., 2001). They are widely used in pharma-
ceuticals and agrochemicals (Tobe et al., 2003); e.g. ﬂuquinco-nazole fungicide for the control of agriculture diseases
(Guang-Fang et al., 2007). Many reports have been published
on the biological activity of quinazoline derivatives, including
their bactericidal, herbal and antitumor activity (Raffa et al.,
1999; Chenard et al., 2001). Thus, their synthesis has been of
great interest in the elaboration of biologically active
heterocyclic compounds. Recently, it was reported that some
quinazolines exhibited very good antimicrobial activity
(Alafeefy, 2008; Desai and Dodiya, 2010). Prompted by these
ﬁndings, the present paper describes the synthesis of an exten-
sion series of 3-substituted-2-phenylquinazolin-4(3H)-one
derivatives and testing of their antimicrobial activity.
Quinolines are known to inhibit DNA synthesis by promot-
ing cleavage of bacterial DNA gyrase and type-IV topoisomer-
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1989; Hooper, 1995; Hardman et al., 2002). Certain drugs based
onquinolinemoiety such as doxorubicin andmitoxantrone have
been established as one of themost effective classes of anticancer
agents in clinical use today with broad application in the treat-
ment of several leukemia and lymphomas as well as in combina-
tion chemotherapy of solid tumors (Wakelin andWaring, 1990).
The potent anticancer activity as well as toxic effects described
for these compounds are normally ascribed, at least, to twomain
mechanisms: one, which is associated with protein, involves
trapping of a protein enzyme–DNA cleavable intermediate,
whereas the other, a non-protein-associated mechanism, is re-
lated to redox cycling of the quinoline moiety, which produces
damaging free-radical species (Murray, 2000).
Similarly, various 4-thiazolidinones (Pan et al., 2010;
Youssef et al., 2010) have attracted considerable attention as
they are also endowed with a wide range of pharmaceutical
activities including anesthetic (Surrey, 1949), anticonvulsant
(Troutman and Long, 1948), antibacterial (Sayyed and Mokle,
2006) andantiviral (RaoandZappala, 2004).Furthermore, drug
research and development have led to the discovery of newphar-
macologically active agents, including imidoxy compounds such
as succinimidoxy (Farror et al., 1993). They also possess a strong
anti-convulsant activity (Edaﬁogho et al., 1991). 4-Thiazolidi-
nones may be considered as phosphate bioisosteres and there-
fore inhibit the bacterial enzyme MurB which is involved inCOOH
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Scheme 1 Preparationthe biosynthesis of peptidoglycan layer of the cell wall (Gursoy
et al., 2005). In addition, some thiazolidinones were recently re-
ported as novel inhibitors of mycobacterial rhamnose synthetic
enzymes (Gursoy et al., 2005). This new approach is believed to
be selective, as rhamnose is not found in humans, but is essential
for mycobacterial cell wall synthesis in animals (Andres et al.,
2000).
Looking to the medicinal importance of 4(3H)-quinazoli-
none, 4-thiazolidinone and quinoline, we report here the synthe-
sis of a new class of heterocyclic molecules in which all of these
moieties are present and try to develop potential bioactive mol-
ecules. The structures of compounds synthesized are assigned
on the basis of IR, 1HNMR, 13CNMR andMass spectral data.
These compounds are evaluated for their antimicrobial screen-
ing on different strains of bacteria and fungi Scheme 1.
2. Experimental
2.1. Materials and methods
All chemicals are of analytical grade and used directly. Melting
points are determined in PMP-DM scientiﬁc melting point
apparatus and are uncorrected. IR spectra are recorded on a
Perkin-Elmer RX 1 FTIR spectrophotometer, using potassium
bromide pellets and the frequencies are expressed in cm1. The
1H NMR and 13C NMR spectra are recorded with a BrukerR N
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908 N.C. Desai, A.M. DodiyaAvance II 400 MHz NMR spectrometer, using tetramethylsil-
ane as the internal reference, with dimethylsulfoxide DMSO-d6
as solvent. The chemical shifts are reported in parts per million
(ppm). Elemental analysis is performed on a Heraeus Carlo
Erba 1180 CHN analyzer. The purity of compounds is
conﬁrmed by TLC using Merck silica gel 60 F254 plates using
n-hexane/ethyl acetate (7:3) as a mobile phase and spots are
visualized under UV radiation. Compound 2-chloro-6-methyl-
quinoline-3-carbaldehyde is synthesized by the literature meth-
od (Bawa and Suresh, 2009).
2.2. Chemistry
2-(4-Chlorophenyl)-4H-benzo[d][1,3]oxazin-4-one (1) (Eissa,
2007) and 3-amino-2-(4-chlorophenyl)quinazolin-4(3H)-one
(2) were synthesized by the literature method (Gao et al.,
2007). Reaction conditions were non-homogeneous and the
use of an excess amount of hydrazine hydrate did not afford
the desired results for procuring the products. When interme-
diate compound (2) reacted with 2-chloro-6-methylquinoline-
3-carbaldehyde by using catalytic amount of acetic acid in eth-
anol, it furnished intermediate (3). Compound (3) reacted with
thioglycolic acid by using anhydrous ZnCl2 as a catalyst and
1,4-dioxan as solvent. Due to the chemical transformation of
compound (3) it produced compound (4), which possessed
4-thiazolidinone nucleus. When compound (4) reacted with
different aromatic aldehydes by using catalytic amount of so-
dium ethoxide and ethanol as a solvent, it produced ﬁnal het-
erocyclic scaffolds (5a–l).
2.2.1. General procedure for 3-(1Z)-1-aza-[2-(2-chloro-6-
methyl(3-quinolyl))vinyl]-2-(4-chlorophenyl)-3-hydroquinaz-
olin-4-one (3)
To a solution of intermediate compound-(2) (0.01 mol) in eth-
anol (20 ml) and 2-chloro-6-methylquinoline-3-carbaldehyde
(0.01 mol) was slowly added to it, in this reaction mixture gla-
cial acetic acid was slowly added as a catalyst. Then reaction
mixture was reﬂuxed for 4–5 h, when the Schiff base came
out, the excess solvent was distilled off and the separated solid
mass ﬁltered and washed with ice-cold methanol, dried and
recrystallized in ethanol. Yield 65%, mp 228 C; IR(KBr,
cm1) m: 3051, 3063 (quinazolinone ring, quinoline ring Ar-
H), 3072 (‚CH stretching), 2959 (–CH3 stretching), 1467 (–
CH3 bending), 1671 (C‚O stretching), 1605, 1580 (C‚N
stretching), 1562–1439 (C‚C, quinazolinone ring, quinoline
ring, benzene ring), 838 (C–Cl stretching); 1H NMR (DMSO):
d (ppm): 2.38 (s, 3H, –CH3 group), 8.60 (s, 1H, ‚CH group),
7.51–9.22 (m, 8H, quinoline & quinazolinone-H), 7.29–7.83
(m, 4H, Ar-H); 13C NMR (DMSO): 21.7, 121.9, 124.1,
126.4, 126.6, 126.7, 126.9, 127.3, 128.1, 129.1, 128.9, 132.5,
133.4, 135.7, 136.6, 137.2, 143.3, 147.7, 148.7, 151.6, 153.6,
165.1, 166.7; GCMS: m/z: 458.07 (M+). Anal. calcd. for
C25H16Cl2N4O: C, 65.37; H, 3.51; N, 12.19. Found: C, 65.24;
H, 3.55; N, 12.23.
2.2.2. General procedure for 2-(2-chloro-6-methyl(3-quinolyl))-
3-[2-(4-chlorophenyl)-4-oxo(3-hydroquinazolin-3-yl))-1,3-
thiazolidin-4-one (4)
To a solution of compound (3) (0.01 mol) in 1,4 dioxane
(50 ml) was added mercapto acetic acid (0.015mole) with stir-
ring and a little amount of anhydrous ZnCl2 was added. The
mixture was reﬂuxed for 10–12 h, after the completion ofreaction, it was cooled and the excess solvent distilled and
poured into sodium bicarbonate solution to neutralize it.
The solid product was ﬁltered and washed with cold water.
The resulting solid was recrystallized in ethanol (99%). Yield
59%, mp 217 C; IR (KBr, cm1) m: 3052, 3068 (quinazolinone
ring, quinoline ring Ar-H), 2959 (–CH3 stretching), 1467
(–CH3 bending), 1677, 1686 (>C‚O stretching), 1609, 1582
(>C‚N stretching), 1564–1448 (C‚C, quinazolinone ring,
quinoline ring, benzene ring), 849 (C–Cl stretching); 1H
NMR (DMSO): d (ppm): 2.37 (s, 3H, –CH3 group), 3.85–
3.95 (bs, 2H, CH2 group), 5.92 (s, 1H, S–CH–N), 7.47–8.26
(m, 8H, quinoline & quinazolinone-H), 7.38–7.53 (m, 4H,
Ar-H); 13C NMR (DMSO): 21.7, 35.6, 57.4, 120.8, 125.8,
126.2, 126.5, 126.6, 126.7, 127.5, 127.3, 129.2, 128.6, 128.9,
130.8, 131.4, 133.4, 135.2, 135.7, 136.4, 143.4, 148.7, 150.8,
156.2, 160.8, 168.8; GCMS: m/z: 532.08 (M+). Anal. calcd.
for C27H18Cl2N4O2S: C, 60.79; H, 3.40; N, 10.50. Found: C,
60.85; H, 3.44; N, 10.52.
2.2.3. General procedure for 2-(2-chloro-6-methyl(3-quinolyl))-
3-[2-(4-chlorophenyl)-4-oxo(3-hydroquinazolin-3-yl)]-5-
[(aryl)methylene]-1,3-thiazolidine-4-ones (5a–l)
A solution of intermediate compound-(4) (0.01 mol) was taken
in ethanol (25 ml) and different aromatic aldehydes (0.01 mol)
were slowly added to it with constant stirring and catalytic
amount of sodium ethoxide (0.01 mol) was added along with
it. The reaction mixture was reﬂuxed for 6–7 h, after the com-
pletion of the reaction, the ﬁnal products (5a–l) were obtained
and excess amount of solvent was distilled out. The crude
product was ﬁltered off and washed with ethanol, dried and
recrystallized in ethanol.
2.2.3.1. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(2-chlorophenyl)-
methylene]-1,3-thiazolidin-4-one (5a). Yield, 70%, yellow
crystalline solid, mp 292–293 C. IR (KBr, cm1) m: 3057,
3065 (C–H stret., quinazolinone ring, quinoline ring, Ar-H),
3080 (‚CH stretching), 2957 (–CH3 stretching), 1675, 1681
(>C‚O stretching), 1605, 1589 (C‚N stretching), 1568,
1445 (C‚C, quinazolinone ring, quinoline ring, aromatic
ring), 1464 (–CH3 bending), 845, 832 (C–Cl stretching), 768
(‚CH bending), 692 (mono substituted benzene ring); 1H
NMR (DMSO) d (ppm): 2.34 (s, 3H, –CH3), 5.92 (s, 1H,
S–CH–N), 7.47–8.24 (m, 8H, quinoline & quinazolinone-H),
7.35–7.92 (m, 8H, Ar-H), 8.03 (s, 1H, ‚CH group); 13C
NMR (DMSO) d (ppm): 21.7, 63.6, 120.8, 125.2, 125.8,
126.5, 126.6, 126.7, 126.9, 127.3, 127.5, 127.8, 128.9, 129.1,
129.3, 129.9, 130.7, 131.4, 133.0, 133.4, 134.0, 135.6, 135.7,
136.4, 138.3, 143.3, 148.7, 150.8, 156.2, 160.6, 164.4; GCMS:
m/z: 654.08 (M+). Anal. calcd. for C34H21Cl3N4O2S: C,
62.25; H, 3.22; N, 8.54. Found: C, 62.28; H, 3.27; N, 8.60.
2.2.3.2. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(3-chlorophenyl)-
methylene]-1,3-thiazolidin-4-one (5b). Yield, 66%, light brown
crystalline solid, mp 148–150 C. IR (KBr, cm1) m: 3053, 3064
(C–H stret., quinazolinone ring, quinoline ring, Ar-H), 3083
(‚CH stretching), 2952 (–CH3 stretching), 1673, 1684
(>C‚O stretching), 1607, 1582 (C‚N stretching), 1569,
1440 (C‚C, quinazolinone ring, quinoline ring, aromatic
ring), 1462 (–CH3 bending), 848, 833 (C–Cl stretching), 769
(‚CH bending), 688 (mono substituted benzene ring); 1H
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CH–N), 7.42–8.24 (m, 8H, quinoline & quinazolinone-H),
7.32–7.82 (m, 8H, Ar-H), 8.08 (s, 1H, ‚CH group); 13C
NMR (DMSO) d (ppm): 21.5, 63.7, 120.7, 125.2, 125.8,
126.4, 126.5, 126.6, 126.7, 127.3, 127.5, 128.0, 128.9, 129.1,
130.3, 130.7, 131.4, 133.4, 134.2, 135.7, 135.6, 136.4, 136.6,
138.3, 143.3, 148.7, 150.7, 156.4, 160.3, 164.6; GCMS: m/z:
654.08 (M+). Anal. calcd. for C34H21Cl3N4O2S: C, 62.25; H,
3.22; N, 8.54. Found: C, 62.29; H, 3.28; N, 8.58.
2.2.3.3. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(4-chlorophenyl)-
methylene]-1,3-thiazolidin-4-one (5c). Yield, 79%, yellow
crystalline solid, mp 244–246 C. IR (KBr, cm1) m: 3057,
3065 (C–H stret., quinazolinone ring, quinoline ring. Ar-H),
3085 (‚CH stretching), 2957 (–CH3 stretching), 1679, 1686
(>C‚O stretching), 1609, 1594 (C‚N stretching), 1572,
1450 (C‚C, quinazolinone ring, quinoline ring, aromatic
ring), 1454 (–CH3 bending), 840, 831 (C–Cl stretching), 761
(‚CH bending), 698 (mono substituted benzene ring); 1H
NMR (DMSO) d (ppm): 2.32 (s, 3H, –CH3), 5.94 (s, 1H, S–
CH–N), 7.47–8.21 (m, 8H, quinoline & quinazolinone-H),
7.34–7.88 (m, 8H, Ar-H), 8.05 (s, 1H, ‚CH group); 13C
NMR (DMSO) d (ppm): 21.5, 63.6, 120.6, 125.2, 125.8,
126.5, 126.6, 126.7, 127.3, 127.5, 128.7, 128.9, 129.0, 129.1,
130.7, 131.4, 132.5, 133.3, 133.4, 135.7, 135.6, 136.4, 138.3,
143.3, 148.7, 150.8, 156.1, 160.5, 164.3; GCMS: m/z: 654.08
(M+). Anal. calcd. for C34H21Cl3N4O2S: C, 62.25; H, 3.22;
N, 8.54. Found: C, 62.27; H, 3.31; N, 8.61.
2.2.3.4. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(2-nitro-
phenyl)methylene]-1,3-thiazolidin-4-one (5d). Yield, 63%,
light brown crystalline solid, mp 145–147 C. IR (KBr, cm
1) m: 3054, 3063 (C–H stret., quinazolinone ring, quinoline
ring, Ar-H), 3089 (‚CH stretching), 2957 (–CH3 stretching),
1674, 1680 (>C‚O stretching), 1611, 1583 (C‚N stretching),
1555, 1440 (C‚C, quinazolinone ring, quinoline ring, aro-
matic ring), 1456 (–CH3 bending), 848, 836 (C–Cl stretching),
772 (‚CH bending), 690 (mono substituted benzene ring); 1H
NMR (DMSO) d (ppm): 2.35 (s, 3H, –CH3), 5.90 (s, 1H, S–
CH–N), 7.40–8.26 (m, 8H, quinoline & quinazolinone-H),
7.28–8.21 (m, 8H, Ar-H), 8.32 (s, 1H, ‚CH group); 13C
NMR (DMSO) d (ppm): 21.8, 63.4, 120.6, 123.7, 125.2,
126.5, 126.6, 127.3, 127.4, 127.5, 128.8, 128.9, 129.1, 130.5,
131.4, 134.7, 135.6, 136.4, 147.7, 126.7, 125.8, 133.4, 135.7,
138.3, 143.3, 148.7, 150.8, 156.4, 160.5, 164.5; GCMS: m/z:
665.07(M+). Anal. calcd. for C34H21Cl2N5O4S: C, 61.26; H,
3.17; N, 10.50. Found: C, 61.29; H, 3.22; N, 10.55.
2.2.3.5. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(3-nitrophenyl)-
methylene]-1,3-thiazolidin-4-one (5e). Yield, 67%, dark yellow
crystalline solid, mp 235–237 C. IR (KBr, cm1) m: 3050, 3067
(C–H stret., quinazolinone ring, quinoline ring, Ar-H), 3080
(‚CH stretching), 2956 (–CH3 stretching), 1671, 1685
(>C‚O stretching), 1604, 1583 (C‚N stretching), 1562,
1452 (C‚C, quinazolinone ring, quinoline ring, aromatic
ring), 1462 (–CH3 bending), 852, 840 (C–Cl stretching), 762
(‚CH bending), 690 (mono substituted benzene ring); 1H
NMR (DMSO) d (ppm): 2.38 (s, 3H, –CH3), 5.95 (s, 1H, S–
CH–N), 7.52–8.24 (m, 8H, quinoline & quinazolinone-H),7.32–8.31 (m, 8H, Ar-H), 8.35 (s, 1H, ‚CH group); 13C
NMR (DMSO) d (ppm): 21.4, 63.8, 120.4, 122.6, 123.1,
125.2, 125.8, 126.5, 126.6, 126.7, 127.3, 127.5, 128.9, 129.1,
129.5, 130.7, 131.4, 133.4, 135.7, 135.6, 134.6, 136.1, 136.4,
138.3, 143.3, 147.8, 148.7, 150.3, 156.0, 160.3, 164.7; GCMS:
m/z: 665.07 (M+). Anal. calcd. for C34H21Cl2N5O4S: C,
61.26; H, 3.17; N, 10.50. Found: C, 61.32; H, 3.23; N, 10.56.
2.2.3.6. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(4-nitrophenyl)-
methylene]-1,3-thiazolidin-4-one (5f). Yield, 70%, light orange
crystalline solid, mp 292–293 C. IR (KBr, cm1) m: 3056, 3069
(C–H stret., quinazolinone ring, quinoline ring, Ar-H), 3080
(‚CH stretching), 2957 (–CH3 stretching), 1671, 1688
(>C‚O stretching), 1612, 1592 (C‚N stretching), 1562,
1451 (C‚C, quinazolinone ring, quinoline ring, aromatic
ring), 1458 (–CH3 bending), 844, 832 (C–Cl stretching), 764
(‚CH bending), 690 (mono substituted benzene ring); 1H
NMR (DMSO) d (ppm): 2.32 (s, 3H, –CH3), 5.98 (s, 1H, S–
CH–N), 7.55–8.23 (m, 8H, quinoline & quinazolinone-H),
7.37–8.22 (m, 8H, Ar-H), 8.38 (s, 1H, ‚CH group); 13C
NMR (DMSO) d (ppm): 21.4, 63.4, 120.5, 123.6, 125.2,
125.8, 126.5, 126.6, 126.7, 127.3, 127.5, 128.9, 129.0, 129.1,
130.7, 131.4, 133.4, 135.6, 135.7, 136.4, 138.3, 141.3, 143.3,
147.1, 148.7, 150.5, 156.2, 160.8, 164.4; GCMS: m/z: 665.07
(M+). Anal. calcd. for C34H21Cl2N5O4S: C, 61.26; H, 3.17;
N, 10.50. Found: C, 61.33; H, 3.24; N, 10.57.
2.2.3.7. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(2-hydroxyphenyl)-
methylene]-1,3-thiazolidin-4-one (5g). Yield, 85%, light brown
crystalline solid, mp 201–203 C. IR (KBr, cm1) m: 3438 (–OH
group stretching), 3053, 3069 (C–H stret., quinazolinone ring,
quinoline ring, Ar-H), 3086 (‚CH stretching), 2957 (–CH3
stretching), 1668, 1684 (>C‚O stretching), 1609, 1583
(C‚N stretching), 1568, 1445 (C‚C, quinazolinone ring,
quinoline ring, aromatic ring), 1464 (–CH3 bending), 841,
837 (C–Cl stretching), 769 (‚CH bending), 692 (mono
substituted benzene ring); 1H NMR (DMSO) d (ppm): 2.37
(s, 3H, –CH3), 5.35 (s, 1H, –OH group), 5.92 (s, 1H, S–CH–
N), 6.72–7.60 (m, 8H, Ar-H), 7.51–8.29 (m, 8H, quinoline &
quinazolinone-H), 8.08 (s, 1H, ‚CH group); 13C NMR
(DMSO) d (ppm): 21.9, 63.4, 116.2, 117.6, 120.8, 121.2,
125.2, 125.8, 126.5, 126.6, 126.7, 127.3, 127.5, 128.9, 129.1,
129.3, 130.7, 131.4, 133.4, 135.6, 135.7, 136.4, 138.3, 143.3,
148.7, 150.8, 157.5, 156.1, 160.4, 164.0; GCMS: m/z: 636.08
(M+). Anal. calcd. for C34H22Cl2N4O3S: C, 64.05; H, 3.47;
N, 8.78. Found: C, 64.09; H, 3.55; N, 8.85.
2.2.3.8. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(3-hydroxyphenyl)-
methylene]-1,3-thiazolidin-4-one (5h). Yield, 70%, off yellow
crystalline solid, mp 252–253 C. IR (KBr, cm1) m: 3432
(–OH group stretching), 3062, 3069 (C–H stret., quinazolinone
ring, quinoline ring, Ar-H), 3080 (‚CH stretching), 2951
(–CH3 stretching), 1671, 1689 (>C‚O stretching), 1608,
1580 (C‚N stretching), 1563, 1442 (C‚C, quinazolinone
ring, quinoline ring, aromatic ring), 1463 (–CH3 bending),
851, 842 (C–Cl stretching), 762 (‚CH bending), 699 (mono
substituted benzene ring); 1H NMR (DMSO) d (ppm): 2.34
(s, 3H, –CH3), 5.38 (s, 1H, –OH group), 5.95 (s, 1H,
S–CH–N), 7.68–8.26 (m, 8H, quinoline&quinazolinone-H),
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Figure 1 Carbon numbering of the ﬁnal compound-5h.
910 N.C. Desai, A.M. Dodiya7.36–8.31 (m, 8H, Ar-H), 8.09 (s, 1H,‚CH group); 13C NMR
(DMSO) d (ppm): 21.7, 63.6, 112.1, 115.1, 120.8, 121.1, 125.2,
125.8, 126.5, 126.6, 126.7, 127.3, 127.5, 128.9, 129.1, 130.0,
130.7, 131.4, 133.4, 135.6, 135.7, 136.4, 136.6, 138.3, 143.3,
148.7, 150.8, 156.2, 158.4, 160.6, 164.4; GCMS: m/z: 636.08
(M+). Anal. calcd. for C34H22Cl2N4O3S: C, 64.05; H, 3.47;
N, 8.78. Found: C, 64.11; H, 3.53; N, 8.84.
2.2.3.9. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(4-hydroxyphenyl)-
methylene]-1,3-thiazolidin-4-one (5i). Yield, 53%, dark brown
crystalline solid, mp 263–265 C. IR (KBr, cm1) m: 3436 (–OH
group stretching), 3056, 3069 (C–H stret., quinazolinone ring,
quinoline ring, Ar-H), 3080 (‚CH stretching), 1670, 1683
(>C‚O stretching), 2956 (–CH3 stretching), 1614, 1590
(C‚N stretching), 1560, 1441 (C‚C, quinazolinone ring,
quinoline ring, aromatic ring), 1462 (–CH3 bending), 846,
835 (C–Cl stretching), 769 (‚CH bending), 691 (mono
substituted benzene ring); 1H NMR (DMSO) d (ppm): 2.36
(s, 3H, –CH3), 5.39 (s, 1H, –OH group), 5.96 (s, 1H, S–CH–
N), 7.63–8.27 (m, 9H, quinoline & quinazolinone-H), 7.28–
7.88 (m, 9H, Ar-H), 8.05 (s, 1H, ‚CH group); 13C NMR
(DMSO) d (ppm): 21.4, 63.8, 115.2, 115.9, 120.9, 125.2,
125.8, 126.5, 126.6, 126.7, 127.3, 127.5, 127.8, 130.6, 130.7,
131.4, 133.4, 135.6, 135.7, 136.4, 138.3, 129.1, 128.9, 143.3,
148.7, 150.8, 156.0, 157.3, 160.9, 164.1; GCMS: m/z: 636.08
(M+). Anal. calcd. for C34H22Cl2N4O3S: C, 64.05; H, 3.47;
N, 8.78. Found: C, 64.12; H, 3.53; N, 8.83.
2.2.3.10. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(4-methylphenyl)-
methylene]-1,3-thiazolidin-4-one (5j). Yield, 74%, off brown
crystalline solid, mp 201–203 C. IR (KBr, cm1) m: 3054,
3068 (C–H stret., quinazolinone ring, quinoline ring, Ar-H),
3082 (‚CH stretching), 1675, 1681 (>C‚O stretching),
2950 (–CH3 stretching), 1605, 1589 (C‚N stretching), 1567,
1442 (C‚C, quinazolinone ring, quinoline ring, aromatic
ring), 1460 (–CH3 bending), 846, 839 (C–Cl stretching), 762
(‚CH bending), 696 (mono substituted benzene ring); 1H
NMR (DMSO) d (ppm): 2.34 (s, 6H, –CH3), 2.39 (s, 3H, –
CH3 group), 5.91 (s, 1H, S–CH–N), 7.76 (s, 1H,‚CH group),
7.47–8.24 (m, 8H, quinoline & quinazolinone-H), 7.18–7.60
(m, 8H, Ar-H); 13C NMR (DMSO) d (ppm): 21.3, 21.7, 63.6,
120.8, 125.2, 125.8, 126.5, 126.6, 126.7, 127.3, 127.5, 128.5,
128.9, 129.1, 130.7, 131.4, 132.2, 133.4, 135.6, 135.7, 136.4,
138.3, 143.3, 148.7, 150.8, 156.2, 157.6, 160.6, 164.4. Anal.
calcd. for C35H24Cl2N4O2S: C, 66.14; H, 3.80; N, 8.81; GCMS:
m/z: 634.11 (M+). Found: C, 66.20; H, 3.86; N, 8.87.
2.2.3.11. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(4-methoxyphenyl)-
methylene]-1,3-thiazolidin-4-one (5k). Yield, 72%, dark yellow
crystalline solid, mp 224–226 C. IR (KBr, cm1) m: 3057, 3062
(quinazolinone ring, quinoline ring Ar-H), 3075 (‚CH
stretching), 2945 (–OCH3 stretching), 1672, 1684 (>C‚O
stretching), 1605, 1589 (C‚N stretching), 1568, 1445 (C‚C,
quinazolinone ring, quinoline ring, aromatic ring), 1465
(–OCH3 bending), 845, 838 (C–Cl stretching), 763 (‚CH
bending), 694 (mono substituted benzene ring); 1H NMR
(DMSO) d (ppm): 2.33 (s, 3H, –CH3), 3.83 (s, 3H, –OCH3
group), 5.94 (s, 1H, S–CH–N), 6.94–7.62 (m, 8H, Ar-H),
7.76 (s, 1H, ‚CH group), 7.41–8.25 (m, 8H, quinoline &quinazolinone-H); 13C NMR (DMSO) d (ppm): 21.6, 55.8,
63.6, 114.2, 120.8, 125.2, 125.8, 126.5, 126.6, 126.7, 127.3,
127.4, 127.5, 128.9, 129.1, 130.0, 130.7, 131.4, 133.4, 135.6,
135.7, 136.4, 138.3, 114.2, 143.3, 148.7, 150.8, 156.2, 159.6,
160.2, 164.2; GCMS: m/z: 650.12 (M+). Anal. calcd. for
C35H24Cl2N4O3S: C, 64.51; H, 3.71; N, 8.59. Found: C,
64.56; H, 3.77; N, 8.64.
2.2.3.12. 2-(2-Chloro-6-methyl(3-quinolyl))-3-[2-(4-chloro-
phenyl)-4-oxo-(3-hydroquinazolin-3-yl)]-5-[(3,4,5-methoxy-
phenyl)methylene]-1,3-thiazolidin-4-one (5l). Yield, 69%,
dark brown crystalline solid, mp 189–191 C. IR (KBr,
cm1) m: 3051, 3062 (quinazolinone ring, quinoline ring, Ar-
H), 3080 (‚CH stretching), 2942 (–OCH3 stretching), 1671,
1682 (>C‚O stretching), 1605, 1585 (C‚N stretching),
1566, 1450 (C‚C, quinazolinone ring, quinoline ring, aro-
matic ring), 1461 (–OCH3 bending), 842 (C–Cl stretching),
763 (‚CH bending), 694 (mono substituted benzene ring);
1H NMR (DMSO) d (ppm): 2.38 (s, 3H, –CH3), 3.83 (s, 9H,
–OCH3 group), 5.96 (s, 1H, S–CH–N), 6.78–7.52 (m, 6H,
Ar-H), 7.72 (s, 1H,‚CH group), 7.49–8.29 (m, 8H, quinoline
& quinazolinone-H); 13C NMR (DMSO) d (ppm): 21.2, 56.2,
60.8, 63.6, 103.8, 120.8, 125.2, 125.8, 126.5, 126.6, 126.7,
127.3, 127.5, 128.9, 129.1, 129.5, 130.7, 131.4, 133.4, 136.4,
135.7, 135.6, 138.3, 138.4, 143.3, 148.7, 150.8, 153.0, 153.4,
156.2, 160.4, 164.7; GCMS: m/z: 710.55 (M+). Anal. calcd.
for C37H28Cl2N4O5S: C, 62.45; H, 3.96; N, 7.87. Found: C,
62.51; H, 3.99; N, 7.93.
3. Results and discussion
Characterization of newly synthesized compounds of the series
is carried out by IR, NMR and Mass spectra and the data is
discussed in the experimental section.
3.1. IR-DATA
IR spectrum of the ﬁnal compound-5h (molecular formula
C34H22Cl2N4O3S, m.w. 636.08, structure and carbon number-
ing is given in Fig. 1) over the 3062 and 3069 cm1 ranges
showed multiple weak absorption peaks corresponding to
Qu-H and Ar-H stretching vibration absorption peaks. The
absorption peak at 3080 cm1 is due to the stretching vibration
of the methylene group. The absorption at 2851 cm1 is due to
stretching vibration of the methyl group. The strong absorp-
tion at 1689 cm1 is due to >C‚O stretching vibration, which
Synthesis, characterization and antimicrobial screening 911is present in thiazolidine ring at position C-15, while another
absorption peak at 1671 cm1 is due to >C‚O stretching
vibration in quinazolinone ring, which is present at position
C-2. Moderate intensity absorptions at 1608 and 1580 cm1
correspond to a >C‚N– stretching vibration. Absorptions
at 1563 and 1442 cm1 are due to the C‚C and skeleton vibra-
tions of aryl and heterocyclic rings. The absorption peak at
1463 cm1 is due to bending vibration of the methyl group.
The broad absorption peak at 3432 cm1 is observed due to
–OH stretching vibration. The absorption peaks at 851 and
842 cm1 are due to chlorine atoms, which are attached to car-
bon atom at C-2 and C-15 in thiazolidine and quinazolinone
rings. The vibration at 762 cm1 is due to bending vibration
of methylene group. The absorption peaks 699 cm1 arise
due to phenyl-substituted at position-3.
3.2. 1H NMR-DATA
It can be seen from the chemical structure of compound-5h that
different pairs of carbons e.g. C-10 and C-14, C-11 and C-13 are
attached to chemically equivalent protons. The protons which
are attached to C-10 and C-14 appeared at 7.39, while protons
which are attached to C-11 and C-13 appeared at 7.52 ppm.
The proton attached to C-5 position appeared as a multiplet
at d = 7.63 ppm due to mutual coupling with protons attached
to C-4 and C-6, while the proton attached to C-6 appeared as a
multiplet at d = 7.70 ppm due to mutual coupling with the pro-
tons attached to C-5 and C-7. The proton attached to C-4 posi-
tion appeared as a doublet at d = 8.03 ppm. A single peak that
appeared at d = 5.92 ppm must be for the proton attached at
C-17 which is present in the thiazolidine ring. A single peak
appeared at d = 5.35 ppm of –OH group which is attached to
C-31. The proton of the methylene group appeared as a singlet
at d = 7.76 ppm. Protons of the phenyl ring (C-30, C-32, C-33
and C-34) appeared between d = 6.70–7.53 ppm, respectively.
The protons of the methyl group appeared as a singlet at
d = 2.43 ppm. The proton of the C-30 appeared as a singlet
at d = 6.70 ppm due to the presence of a hydroxyl group at
C-31, while the proton of the C-32 appeared as a doublet at
d = 6.83 ppm due to the presence of a hydroxyl group at C-
31. The proton attached to C-33 position appeared as a multi-
plet at d = 7.53 ppm due to mutual coupling with protons
attached to C-32 and C-34. Proton of C-25 appeared as a sin-
glet at d = 7.63 ppm due to the presence of methyl group at
C-23, while proton of C-22 appeared as a doublet at
d = 7.47 ppm due to the presence of methyl group at C-23.
3.3. 13C NMR-DATA
The ﬁnal compound-5h has quinazolinone ring, quinoline ring
and thiazolidine ring. Chemical shifts of ﬁnal compound
carbons vary from d = 164.4 to 21.7 ppm. The carbon nuclei
under the inﬂuence of a strong electronegative environment
appeared downﬁeld, e.g. C-2 and C-15 carbonyl, which are
directly linked to the ring nitrogen, have a chemical shift value
of d = 160.8 and 164.4 ppm, respectively, whereas C-19 linked
to a chlorine atom appeared at d = 150.8 ppm. Carbon C-1
which is attached on both sides to nitrogen atoms appeared
at d = 156.2. Carbon of methylene group C-28 appeared at
d = 125.2 ppm. Carbon of the methyl group C-24 appeared
at d = 21.7 ppm, while carbon C-23, where the methyl group
is attached appeared at d = 136.4 ppm. Chemical shift of thering carbons at C-3 and C-16 which are affected by the presence
of the nearest carbonyl group appeared at d = 120.8 and
138.3 ppm, respectively. Carbons of benzene ring which are at-
tached to quinazolinone ring having equivalent carbons C-10
and C-14 appeared at d = 129.1 ppm, C-11 and C-13 appeared
at d = 128.9 ppm respectively, while carbon C-12, which is
directly attached with highly electro negative chlorine atom ap-
peared at d = 135.7 ppm. While the carbon atom C-17, which
is present in the thiazolidine ring between the nitrogen atom
and sulfur atom appeared at d = 63.6 ppm. The carbon C-31
which is directly attached to hydroxyl group appeared at
d = 158.4 ppm, the other carbons of this ring (C-29, C-30,
C-32, C-33 and C-34) appeared between d = 112.1–136.6
ppm, respectively. The carbons of the quinoline ring (C-18,
C-20, C-21, C-22, C-25, C-26 and C-27) appeared between
d = 125.8 and 143.4 ppm, respectively. Structure and carbon
numbering of compound-5h is described in Fig. 1.
3.4. Antimicrobial activity
Many of the newly synthesized compounds are found to exhi-
bit good to excellent antimicrobial activity. From antimicro-
bial activity data (Table 1), it is observed that compounds
5c(-4-Cl), 5g(-2-OH) and 5h(-3-OH) are the most active com-
pounds. Data of antibacterial activity reveals that, compounds
5a (-2-Cl), 5d (-2-NO2), 5g (-2-OH) and 5j (-4-CH3) are consid-
ered to be good active against Escherichia coli, while com-
pounds 5c (-4-Cl) and 5l (-3,4,5-(OCH3)2) are considered as
very good active against E. coli. Similarly when we have taken
the -3-OH group as substitution in compound 5h, it shows
excellent activity against E. coli. Compounds 5b (-3-Cl), 5c
(-4-Cl) and 5i (-4-OH) are considered as good active against
Pseudomonas aeruginosa. When we change the substitution in
compounds 5h and 5k by 3-hydroxy and 4-methoxy groups,
they exhibit very good activity against P. aeruginosa.
Compounds 5d (-2-NO2) is considered as good active against
Staphylococcus aureus, while compounds 5b (-3-Cl), 5c
(-3-Cl), 5f (-4-NO2), 5h (-3-OH), 5i (-4-OH) and 5l (-3,4,5-
(OCH3)2) are considered as very good active against S. aureus.
When we have replaced -2-OH group as a substitution in com-
pound 5g, it is an excellent active compound against S. aureus.
Compounds 5b (-3-Cl), 5h (-3-OH) and 5k (-4-OCH3) are con-
sidered as good active against Streptococcus pyogenes, while
compound 5i (-4-OH) is considered as very good active against
S. pyogenes. For the antifungal activity, we have screened the
same compounds which are used for antibacterial activity.
Compounds 5a (-2-Cl), 5c (-3-Cl), 5e (-3-NO2), 5g (-2-OH),
5i (-4-OH) and 5k (-4-OCH3) are considered as good active
against Candida albicans, while compounds 5b (-3-Cl), 5d (-2-
NO2), 5f (-4-NO2) and 5h (-3-OH) are considered as excellent
active against C. albicans. Compounds 5c (-3-Cl), 5g (-2-OH),
5i (-4-OH) and 5l (-3,4,5-(OCH3)2) are considered as good
active against Aspergillus niger. Compounds 5a (-2-Cl), 5e
(-3-NO2) and 5g (-2-OH) are considered as good active against
Aspergillus clavatus. Thus we have discussed and compared
antibacterial and antifungal activities based on standard drugs
ampicillin and griseofulvin, respectively.
3.4.1. Antibacterial activity
For the antibacterial activity, the newly synthesized com-
pounds are screened for their antibacterial activity against
Gram positive bacteria S. aureus (MTCC-96) and S. pyogenes
Table 1 Results of antibacterial and antifungal screening of the compounds (5a–l).
Sr. No. -Ar Minimum inhibitory concentration (MIC) lg/ml ± SD Minimum inhibitory concentration (MIC) in lg/ml ± SD
E. coli
MTCC 443
P. aeruginosa
MTCC 1688
S. aureus
MTCC 96
S. pyogenes
MTCC 442
C. albicans
MTCC 227
A. niger
MTCC 282
A. clavatus
MTCC 1323
5a -2-Cl 100 ± 3.56* 250 ± 4.04* 500 ± 4.93* 200 ± 3.46* 500 ± 3.15* 500 ± 3.60* 100 ± 3.05*
5b -3-Cl 250 ± 3.05* 100 ± 3.51* 100 ± 4.72* 100 ± 3.15* 100 ± 4.04* 1000 ± 3.51* 1000 ± 4*
5c -4-Cl 50 ± 4.04* 100 ± 4.50* 100 ± 4.93* 500 ± 4.04* 500 ± 3.21* 100 ± 4.35* 500 ± 3.78*
5d -2-NO2 100 ± 3.78
* 125 ± 4* 250 ± 34.04* 500 ± 4.58* 100 ± 4.58* 500 ± 3.78* 500 ± 3.05*
5e -3-NO2 500 ± 3.05
* 500 ± 1* 500 ± 3.78* 250 ± 4.08* 500 ± 4.04* 200 ± 4.50* 100 ± 3.60*
5f -4-NO2 250 ± 2.51
* 500 ± 3.51* 100 ± 4.04* 500 ± 3.46* 100 ± 4.50* 1000 ± 4.58* 500 ± 4.04*
5g -2-OH 100 ± 3.51* 500 ± 1* 50 ± 4.93* 500 ± 4.58* 500 ± 3.51* 100 ± 4.04* 100 ± 4.04*
5h -3-OH 25 ± 4.04* 50 ± 1.32* 100 ± 4* 100 ± 3.60* 100 ± 3.21* 500 ± 3.05* 200 ± 4.16*
5i -4-OH 250 ± 3* 100 ± 4.04* 100 ± 3.78* 50 ± 4.04* 500 ± 3.51* 100 ± 3.51* 500 ± 3*
5j -4-CH3 100 ± 3.21
* 500 ± 4.16* 500 ± 3.21* 500 ± 3.51* 1000 ± 3.05* 1000 ± 3.05* 1000 ± 4.04*
5k -4-OCH3 500 ± 3.51
* 50 ± 2.08* 500 ± 3.21* 100 ± 3.05* 500 ± 3.78* 500 ± 4.16* 200 ± 3.05*
5l -3,4,5-(OCH3)3 62.5 ± 3.05
* 500 ± 3.60* 100 ± 4.58* 500 ± 3.51* 1000 ± 3.05* 100 ± 4.04* 500 ± 2.51*
Ampicillin 100 ± 1.52* 100 ± 2.08* 250 ± 2.0* 100 ± 1.0* – – –
Griseofulvin – – – – 500 ± 0.57* 100 ± 1* 100 ± 1.15*
SD= Standard deviation.
* p 6 0.0001.
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P. aeruginosa (MTCC-1688)]. Antibacterial activity is carried
out by serial broth dilution method (Ghalem and Mohamed,
2009; Desai and Trivedi, 1993). The standard strains used
for antimicrobial activity were procured from Institute of
Microbial Technology, Chandigarh. Compounds (5a–l) are
screened for their antibacterial activity in triplicate against
E. coli, S. aureus, P. aeruginosa and S. pyogenes at different
concentrations of 1000, 500, 200, 100, 50, 25 lg/ml as shown
in (Table 1). The drugs which are found to be active in primary
screening are similarly diluted to obtain 100, 50, 25, 12.5 lg/ml
concentrations. 10 lg/ml suspensions are further inoculated on
appropriate media and growth is noted after 24 and 48 h. The
lowest concentration, which showed no growth after spot sub-
culture is considered asMIC for each drug. The highest dilution
showing at least 99% inhibition is taken as (MIC). The test
mixture should contain 108 cells/ml. The standard drug used
in the present study is ‘ampicillin’ for evaluating antibacterial
activity which shows (100, 100, 250 and 100 lg/mL) MIC
against E. coli, P. aeruginosa, S. aureus and S. pyogenes, respec-
tively. For bacterial growth, in the present protocol, we have
used Muller Hinton broth at 37 C in aerobic condition for
24 h to 48 h.
3.4.2. Antifungal activity
While for the antifungal activity, same compounds are tested
for antifungal activity in triplicate against C. albicans, A niger
andA. clavatus at various concentrations of 1000, 500, 200 and
100 lg/ml as shown in (Table 1). The results are recorded in
the form of primary and secondary screening. Synthesized
compounds are diluted at 1000 lg/ml concentration, as a stock
solution. Synthesized compounds which are found to be active
in this primary screening are further tested in a second set of
dilution against all microorganisms. The lowest concentration,
which shows no growth after spot subculture is considered as
(MIC) for each drug. The highest dilution showing at least
99% inhibition is taken as MIC. The test mixture should con-
tain 108 spores/ml MIC. ‘Griseofulvin’ is used as a standard
drug for antifungal activity, which shows (500, 100 and
100 lg/mL) MIC against C. albicans, A. niger and A. clavatus,respectively. In the present protocol for fungal growth, we
have used Sabourauds dextrose broth at 22 C in aerobic con-
dition for 72 h. The results of antimicrobial evaluation of
derivatives (5a–l) are collected in (Table 1).
3.4.3. Statistical analysis
The standard deviation value is expressed in terms of ±SD.
On basis of the calculated value by using ANOVA method,
it has been observed that the differences below 0.0001 level
(p 6 0.0001) are considered as statistically signiﬁcant.4. Conclusion
Some of the newly synthesized compounds exhibited promising
antibacterial activity against E. coli, P. aeruginosa, S. aureus
and S. pyogenes strains, while antifungal activity against
C. albicans, A. niger and A. clavatus strains. Compounds 5g
and 5h possess excellent activity against both bacterial and fun-
gal species. It seems that the hydroxy group at ortho and meta
position are very signiﬁcant for enhancing activity against both
bacterial and fungal species. Results biological activities of no-
vel quinoline based quinazolinone,4-thiazolidine derivatives
are interesting for optimization of lead molecules for further
generation of antimicrobial agents.Acknowledgments
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